Jazz Pharmaceuticals plc P/E Ratio 2009–2025
Jazz Pharmaceuticals plc reported 14.24 of price-to-earnings ratio for fiscal 2024. That was 29.4% lower than fiscal 2023. Compared with fiscal 2019, the change was -13.3%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | 14.24 | -29.4% |
| FY 2023 | 20.16 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | 39.11 | +138.2% |
| FY 2019 | 16.42 | -3.3% |
| FY 2018 | 16.98 | +0.4% |
| FY 2017 | 16.92 | -0.5% |
| FY 2016 | 17.01 | -36.7% |
| FY 2015 | 26.88 | -84.7% |
| FY 2014 | 176.05 | +388.3% |
| FY 2013 | 36.06 | +224.3% |
| FY 2012 | 11.12 | -23.2% |
| FY 2011 | 14.47 | -39.0% |
| FY 2010 | 23.71 | — |
| FY 2009 | — | — |
Source: Jazz Pharmaceuticals plc SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open JAZZ 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Jazz Pharmaceuticals plc reported 14.24 of price-to-earnings ratio for fiscal 2024. That was 29.4% lower than fiscal 2023. Compared with fiscal 2019, the change was -13.3%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Jazz Pharmaceuticals plc
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeJazz Pharmaceuticals plc — frequently asked questions
What is Jazz Pharmaceuticals plc's price-to-earnings ratio?
Jazz Pharmaceuticals plc (JAZZ) reported price-to-earnings ratio of 14.24 for fiscal year 2024, per its SEC filings.
How has Jazz Pharmaceuticals plc's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, JAZZ's price-to-earnings ratio declined at roughly 3.1% per year (compound annual rate), from 23.71 to 14.24.
Where does this data come from?
Figures are computed from Jazz Pharmaceuticals plc's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More JAZZ financial history
Full JAZZ fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →